Pharma Reviews: DSP's Gopal Agarwal on why he has bought into market correction

In terms of the pharma sector valuation, it has derated materially because of issues in US business. We are still seeing 8-10% top line growth in India.
Read more: DSP's Gopal Agarwal on why he has bought into market correction